These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 17852405)

  • 1. VEGF-related protein isolated from Vipera palestinae venom, promotes angiogenesis.
    Brown MC; Calvete JJ; Staniszewska I; Walsh EM; Perez-Liz G; Del Valle L; Lazarovici P; Marcinkiewicz C
    Growth Factors; 2007 Apr; 25(2):108-17. PubMed ID: 17852405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2.
    Chung TW; Kim SJ; Choi HJ; Kim KJ; Kim MJ; Kim SH; Lee HJ; Ko JH; Lee YC; Suzuki A; Kim CH
    Glycobiology; 2009 Mar; 19(3):229-39. PubMed ID: 18974200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of fractalkine/CX3CR1 by vascular endothelial cells induces angiogenesis through VEGF-A/KDR and reverses hindlimb ischaemia.
    Ryu J; Lee CW; Hong KH; Shin JA; Lim SH; Park CS; Shim J; Nam KB; Choi KJ; Kim YH; Han KH
    Cardiovasc Res; 2008 May; 78(2):333-40. PubMed ID: 18006432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial growth factor (VEGF)-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of coreceptor binding and deficient regulation of kinase activity.
    Kawamura H; Li X; Harper SJ; Bates DO; Claesson-Welsh L
    Cancer Res; 2008 Jun; 68(12):4683-92. PubMed ID: 18559514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lebectin, a Macrovipera lebetina venom-derived C-type lectin, inhibits angiogenesis both in vitro and in vivo.
    Pilorget A; Conesa M; Sarray S; Michaud-Levesque J; Daoud S; Kim KS; Demeule M; Marvaldi J; El Ayeb M; Marrakchi N; Béliveau R; Luis J
    J Cell Physiol; 2007 May; 211(2):307-15. PubMed ID: 17323383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential role of platelet granular mediators in angiogenesis.
    Brill A; Elinav H; Varon D
    Cardiovasc Res; 2004 Aug; 63(2):226-35. PubMed ID: 15249180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway.
    Jung MH; Lee SH; Ahn EM; Lee YM
    Carcinogenesis; 2009 Apr; 30(4):655-61. PubMed ID: 19228635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis.
    Scaldaferri F; Vetrano S; Sans M; Arena V; Straface G; Stigliano E; Repici A; Sturm A; Malesci A; Panes J; Yla-Herttuala S; Fiocchi C; Danese S
    Gastroenterology; 2009 Feb; 136(2):585-95.e5. PubMed ID: 19013462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ethyl pyruvate, an anti-inflammatory agent, inhibits tumor angiogenesis through inhibition of the NF-κB signaling pathway.
    Park SY; Yi EY; Jung M; Lee YM; Kim YJ
    Cancer Lett; 2011 Apr; 303(2):150-4. PubMed ID: 21333439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor anti-angiogenic effect and mechanism of action of delta-tocotrienol.
    Shibata A; Nakagawa K; Sookwong P; Tsuzuki T; Oikawa S; Miyazawa T
    Biochem Pharmacol; 2008 Aug; 76(3):330-9. PubMed ID: 18599020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis.
    Carmi Y; Voronov E; Dotan S; Lahat N; Rahat MA; Fogel M; Huszar M; White MR; Dinarello CA; Apte RN
    J Immunol; 2009 Oct; 183(7):4705-14. PubMed ID: 19752225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
    Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
    Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrigel cytometry: a novel method for quantifying angiogenesis in vivo.
    Adini A; Fainaru O; Udagawa T; Connor KM; Folkman J; D'Amato RJ
    J Immunol Methods; 2009 Mar; 342(1-2):78-81. PubMed ID: 19109967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VEGFR-2 antagonist SU5416 attenuates bleomycin-induced pulmonary fibrosis in mice.
    Ou XM; Li WC; Liu DS; Li YP; Wen FQ; Feng YL; Zhang SF; Huang XY; Wang T; Wang K; Wang X; Chen L
    Int Immunopharmacol; 2009 Jan; 9(1):70-9. PubMed ID: 18976720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VEGF and inhibitors of TGFbeta type-I receptor kinase synergistically promote blood-vessel formation by inducing alpha5-integrin expression.
    Liu Z; Kobayashi K; van Dinther M; van Heiningen SH; Valdimarsdottir G; van Laar T; Scharpfenecker M; Löwik CW; Goumans MJ; Ten Dijke P; Pardali E
    J Cell Sci; 2009 Sep; 122(Pt 18):3294-302. PubMed ID: 19706683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 15(S)-hydroxyeicosatetraenoic acid-induced angiogenesis requires STAT3-dependent expression of VEGF.
    Srivastava K; Kundumani-Sridharan V; Zhang B; Bajpai AK; Rao GN
    Cancer Res; 2007 May; 67(9):4328-36. PubMed ID: 17483346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Xanthine oxidase interaction with vascular endothelial growth factor in human endothelial cell angiogenesis.
    Kou B; Ni J; Vatish M; Singer DR
    Microcirculation; 2008 Apr; 15(3):251-67. PubMed ID: 18386220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular endothelial growth factor receptor-1 regulates postnatal angiogenesis through inhibition of the excessive activation of Akt.
    Nishi J; Minamino T; Miyauchi H; Nojima A; Tateno K; Okada S; Orimo M; Moriya J; Fong GH; Sunagawa K; Shibuya M; Komuro I
    Circ Res; 2008 Aug; 103(3):261-8. PubMed ID: 18583712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin-like growth factor binding protein-7 (IGFBP7) blocks vascular endothelial cell growth factor (VEGF)-induced angiogenesis in human vascular endothelial cells.
    Tamura K; Hashimoto K; Suzuki K; Yoshie M; Kutsukake M; Sakurai T
    Eur J Pharmacol; 2009 May; 610(1-3):61-7. PubMed ID: 19374835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis.
    La DS; Belzile J; Bready JV; Coxon A; DeMelfi T; Doerr N; Estrada J; Flynn JC; Flynn SR; Graceffa RF; Harriman SP; Larrow JF; Long AM; Martin MW; Morrison MJ; Patel VF; Roveto PM; Wang L; Weiss MM; Whittington DA; Teffera Y; Zhao Z; Polverino AJ; Harmange JC
    J Med Chem; 2008 Mar; 51(6):1695-705. PubMed ID: 18311900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.